The UK Autumn Budget and Ireland’s Budget 2027 have both landed with changes for businesses that invest in innovation. The UK has focused on simplification and wider support for high-growth companies, while Ireland has chosen to enhance its existing R&D tax credit.
For businesses operating across the UK and Ireland, or considering investing in either country, it is useful to consider the two Budgets side by side. While the nature and scale of the changes are different, together they illustrate how each country is seeking to support businesses investing in R&D, growth and innovation.
Here is what each Budget means in practice.
What the UK and Irish R&D changes mean for businesses that invest in innovation
The UK: a focus on simpler claims
After a number of changes seen over the last few years, this Budget brought a lighter touch on R&D, with the emphasis on making the claims process easier for businesses to navigate.
The problem the changes address
Recent changes have increased the administrative burden on genuine R&D claimants. First-time claimants, and some businesses that haven’t claimed recently, may need to submit a Claim Notification Form to HMRC in advance, and all claimants now have to provide an Additional Information Form. The Budget changes are intended to simplify the administration of the reliefs and reduce the administrative burden for businesses making genuine claims.
What has been announced
- R&D Claim Notification Form removed. The Government will remove the requirement to submit a Claim Notification Form for R&D claims made on or after 1 April 2027. Until then, the existing notification requirements continue to apply.
- Simpler Additional Information Form. The form will be simplified from autumn 2027.
- New Founders’ Relief. The Government proposes a 10% Capital Gains Tax rate on up to £10 million of lifetime qualifying gains for eligible founders and early investors in high-growth, innovative companies from April 2027. The detailed eligibility conditions remain subject to consultation, but innovation, including R&D, forms part of the proposed framework. This creates an interesting link between investing in innovation, growing a business and ultimately rewarding founders on exit.
- Wider investment. Alongside the tax measures, there is further investment in areas including access to growth finance, AI and strategic technologies.
Overall, the direction is positive. Making the claims process simpler is welcome, but the bigger picture is how the UK supports innovative businesses to start, grow and scale. Founders’ Relief in particular is still a proposal, with the detailed eligibility conditions subject to consultation.
Ireland: enhancing the existing R&D tax credit
The Irish Budget builds on a series of enhancements made to the R&D tax credit over recent years. The headline credit rate remains at 35%, with the latest measures focused on cash flow, collaboration and recognising a wider range of the costs associated with undertaking R&D.
The problem the changes address
Businesses increasingly combine their own in-house R&D capability with universities, research organisations and external specialists, and there have historically been limits on how much of that outsourced expenditure can qualify. The timing of receiving the credit can also be particularly important for smaller and scaling businesses, where it can have a real cash-flow impact.
What has been announced
- Higher first-year payment threshold. The threshold increases from €87,500 to €105,000, a cash-flow benefit that helps businesses with smaller R&D tax credit claims access more of the benefit sooner.
- More room for outsourced R&D. The limit on qualifying outsourced R&D increases from the greater of 15% of in-house R&D expenditure or €100,000, to the greater of 20% or €200,000. This gives businesses greater flexibility to work with universities, research organisations and unconnected specialist external providers, although not all external expenditure will automatically qualify.
- New 5% uplift linked to qualifying R&D wage costs. This recognises some of the wider supporting costs of carrying out R&D, although further detail is still required on precisely how the measure will operate.
- Knowledge Development Box extended. Ireland’s Knowledge Development Box is being extended for another five years, continuing support from undertaking R&D through to commercialising qualifying intellectual property.
- Simplification for regulated clinical trials. The Irish Budget also proposes that regulated clinical trials can be used to satisfy the science test for R&D tax credit purposes. This may be particularly relevant to businesses in the life sciences sector, although the detail is still to be confirmed.
Two approaches, one message
The UK is focused on simplifying the claims process, while Ireland is more directly enhancing elements of the existing credit. For groups with operations in both countries, that difference can influence where R&D activity is based, how work is shared with universities and external specialists, and how quickly the benefit is received. For businesses weighing up an investment in either country, it is a reminder that the right choice depends on more than the headline relief. The wider message from both Budgets is similar: R&D tax relief should not be looked at in isolation.
Businesses should think about
- How the innovation will be funded, including how R&D tax relief interacts with grants, external investment and growth finance in each country.
- Where the people, internal capability and external expertise needed to carry out the R&D will be located, including collaboration with universities, research organisations and specialist providers.
- How the resulting innovation and intellectual property will be owned, protected and commercialised, including the potential relevance of the Knowledge Development Box and incentives for founders and key people. Tax incentives are relevant factors, but they should not drive these commercial decisions in isolation.
R&D tax relief is an important part of that picture, but it works best as one part of a joined-up plan, whether a business already operates in both countries or is weighing up where to invest next.
If you would like to discuss how the UK or Irish changes may affect your R&D activity, investment plans or wider innovation strategy, our corporate tax team would be glad to help. Get in touch with Chris Webster, Shane Martin, or your usual AAB contact.
How AAB can help
Corporate Tax
AAB’s Corporate Tax service supports businesses at every stage by minimising liabilities and simplifying complex tax rules - so you can focus on growth. Their team offers clear, practical advice on extracting profits, group structuring, capital allowances, loss utilisation, and managing capital gains, tailored to suit both day-to-day needs and long‑term ambitions.
They’re champions for owner‑managed businesses. AAB advises on the right business structure - sole trader, company, LLP - while creating tax‑efficient strategies for profit withdrawal, succession, and exits.
If you’re expanding overseas, AAB's international tax experts guide you through cross‑border structuring. They’ll help you understand global corporation tax regimes, CFC rules, tax residence, withholding taxes, double tax relief, and foreign compliance.
In short, AAB cuts through tax confusion. They offer proactive planning and hands‑on support to help reduce your tax bill, streamline compliance, and support your goals at home and abroad - all delivered in a friendly, human-first way.
View our corporate tax service